Dizal Pharmaceutical announced that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). In February 2022, golidocitinib received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the same indication, making it the first and only innovative drug in China to receive this recognition for PTCL. Golidocitinib, a JAK1-only inhibitor.

PTCL is an aggressive non-Hodgkin lymphoma (NHL) that represents approximately 7% to 10% of NHLs worldwide. The primary endpoint of the study, objective response rate (ORR) assessed by an independent review committee (IRC), reached 44.3%, with a complete response rate (CRR) of 23.9%. Anti-tumor efficacy was observed across different PTCL subtypes and irrespective of the patients' prior treatment history.

The majority of treatment-related adverse events (TRAEs) could be monitored and well managed in the clinic. These findings, highlighting the superior efficacy and safety of golidocitinib., have been widely acknowledged at prestigious conferences such as ASCO, EHA, ICML, and ASH with five oral presentations for four consecutive years. Recently, the Phase I clinical data of golidocitinIB for the treatment of r/rPTCL (JACKPOT8 PARTA) was published in the deemed peer-reviewed journal, Annals of Oncology (Impact Factor: 51.8).